The KNOCOUT PE study will measure how hospitals and patients are benefitting from a new standard of care in the treatment of Pulmonary Embolism utilizing EKOS® therapy with faster, and even safer protocols, proven effective in the OPTALYSE PE study. Presented in May, the OPTALYSE PE study found pulmonary embolism can be treated effectively with EKOS® therapy over a much shorter period and at safer thrombolytic doses far below the previous standard.
On the launch, BTG Vice President of Clinical Development Lynn Allen said, “We are excited to launch a large international registry of EKOS use including the duration of ultrasound and the dose of thrombolytic, in submassive PE. KNOCOUT PE permits a review of how interventionalists are implementing the OPTALYSE PE protocols and the results they are finding in real world practice.” Allen added, “This importantly expands our clinical evidence to understand how clinical study findings such as these are adopted and what new best practices can be shared.”
At full enrollment, KNOCOUT PE is expected to include up to 100 centers internationally. Cases will include those from before and after the release of the OPTALYSE PE study.
Principal investigator of the study, Dr. Keith Sterling of Inova Alexandria Hospital said, “The results of the OPTALYSE PE trial suggest that a new standard for PE treatment might be adopted, the question is how are institutions adjusting to these new low dose, shorter duration treatments and what are they finding.” Sterling concluded, “KNOCOUT PE accelerates the sharing and learning process and continues to build on the body of clinical evidence, including the ULTIMA and SEATTLE II studies.”